Mid-term outcomes of the Absorb BVS versus second-generation DES: A systematic review and meta-analysis

Cordula M. Felix¹, Victor J. van den Berg¹, Sanne E. Hoeks¹, Jiang Ming Fam², Mattie Lenzen¹, Eric Boersma¹, Peter C. Smits³, Patrick W. Serruys⁴, Yoshinobu Onuma¹, Robert Jan M. van Geuns¹.†*  
¹ Thorax centre, Erasmus Medical Centre, Rotterdam, the Netherlands, ² Cardiology department, National Heart Centre Singapore, Singapore, ³ Cardiology department, Maasstad Hospital, Rotterdam, the Netherlands, ⁴ Cardiology department, The National Heart and Lung Institute, Imperial College London, London, United Kingdom, ⁵ Cardiology department, Radboud UMC, Nijmegen, the Netherlands

Abstract

Background
Bioreabsorbable Vascular Scaffolds (BVS) were introduced to overcome some of the limitations of drug-eluting stent (DES) for PCI. Data regarding the clinical outcomes of the BVS versus DES beyond 2 years are emerging.

Objective
To study mid-term outcomes.

Methods
We searched online databases (PubMed/Medline, Embase, CENTRAL), several websites, meeting presentations and scientific session abstracts until August 8th, 2017 for studies comparing Absorb BVS with second-generation DES. The primary outcome was target lesion failure (TLF). Secondary outcomes were all-cause mortality, myocardial infarction, target lesion revascularization (TLR) and definite/probable device thrombosis. Odds ratios (ORs) with 95% confidence intervals (CIs) were derived using a random effects model.

Results
Ten studies, seven randomized controlled trials and three propensity-matched observational studies, with a total of 7320 patients (BVS n = 4007; DES n = 3313) and a median follow-up duration of 30.5 months, were included. Risk of TLF was increased for BVS-treated patients (OR 1.34 [95% CI: 1.12–1.60], p = 0.001, I² = 0%). This was also the case for all myocardial infarction (1.58 [95% CI: 1.27–1.96], p<0.001, I² = 0%), TLR (1.48 [95% CI: 1.19–1.85], p<0.001, I² = 0%) and definite/probable device thrombosis (of 2.82 [95% CI: 1.86–3.89], p<0.001 and I² = 40.3%). This did not result in a difference in all-cause mortality.
At mid-term follow-up, BVS was associated with an increased risk of TLF, MI, TLR and definite/probable device thrombosis, but this did not result in an increased risk of all-cause mortality.

Introduction
Bioresorbable scaffolds, developed to overcome some of the (late) adverse events of metallic drug-eluting stents (DES), are the latest innovation in the treatment of coronary artery disease. The Absorb bioresorbable vascular scaffold (BVS, Abbott Vascular, Santa Clara, CA, USA) is the most intensively studied. The first-in-man study in 2006 revealed promising results and this new device received a CE-mark in 2011 and became commercially available in Europe in September 2012. FDA approval followed in 2016 [1].

The concept of the Absorb BVS consists of treatment of obstructive coronary artery disease with temporary support of the vessel wall while avoiding the acute complications of balloon angioplasty. It was hypothesized that complete resorption would result in restoration of vaso-motion, a reduction in angina, and the avoidance of caging of the vessels or interference with non-invasive imaging. In addition, vessel geometry would be less affected after implantation of a BVS. This should result in better outcomes for patients, with reduced late event rates. Pooled individual data from the four largest randomized controlled trials (RCTs) comparing BVS with second-generation DES did support the concept of temporary support of the artery and showed non-inferiority of the device during the first year [2]. However, several meta-analyses that included data beyond 1 year revealed higher event rates of myocardial infarction, target lesion revascularization and scaffold thrombosis [3, 4]. Data on the performance of BVS beyond 1 year primarily came from small registries, propensity-matched observational studies and a few RCTs. These raised concerns about the occurrence of very late (after 1 year) scaffold thrombosis [5], whereas RCTs assessed only the mid-term time points. We therefore undertook this systematic review and meta-analysis, and report the mid-term clinical outcomes of the Absorb BVS compared with second-generation DES.

Methods
Data sources and study selection
Inclusion criteria for our study were RCTs comparing the Absorb BVS with the Xience CoCr-EES, a second-generation DES, in patients with coronary artery disease with > 12 months of follow-up available. As randomized mid- to long-term data are scarce, we also allowed propensity-matched observational studies comparing BVS with second-generation DES. Both full-length manuscripts and meeting presentations (containing unpublished data) were included. All studies had to report on the outcomes of interest and be written in English. Exclusion criteria were non-human studies, single-arm studies, imaging-only studies, studies with short follow-up (< 12 months), studies in <100 patients, review articles, case series, trial design articles, comparisons other than Absorb BVS versus second-generation DES, studies with duplicate data, and those where the scaffold or stent was implanted elsewhere than in the coronary
artery. This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines [6] (S4 Table).

**Data extraction and quality assessment**

On August 8th, 2017, a medical librarian (WB) conducted a systematic search of the online databases Medline/PubMed, Embase and Cochrane Central Register of Controlled Trials (CENTRAL), several websites (e.g. http://www.clinicaltrials.gov) and scientific session abstracts and oral presentations from conferences, with the following keywords and corresponding MeSH terms: “drug-eluting stent(s)”, “everolimus-eluting stent”, “bioresorbable vascular stent”, “bioresorbable scaffold”. On October 31th, during the 2017 TCT congress, ABSORB II, III and TROFI II presented their 3- and 4-year outcomes, which we also included in our analysis. The bibliographic records retrieved were imported and de-duplicated in Endnote bibliographic software. Two physician reviewers (CF and VB) independently screened the records for eligibility at title or abstract level. Records that were relevant were downloaded and full text manuscripts or meeting presentations were reviewed. Differences between reviewers regarding study selection or data extraction were resolved by consensus. If one study had multiple publications with different follow-up lengths, the most recent follow-up record was used.

Quality and risk of bias in reporting data were assessed according to the Cochrane Handbook of Systematic Reviews [7] and by using the Newcastle-Ottawa Quality Assessment scale for case-control studies (maximum score = 9, meaning low risk of bias). Publication bias for the primary endpoint was assessed using funnel plot.

**Outcomes and definitions**

The primary outcome for this analysis was target lesion failure (TLF), a composite endpoint that consists of cardiac death, target-vessel myocardial infarction and ischemia-driven TLR. Secondary outcomes were all-cause mortality, all myocardial infarction, ischemia-driven TLR and definite or probable device thrombosis. Deaths were considered cardiac unless a non-cardiac cause was identified. TLR was described as any repeated revascularization of the target lesion. Device thrombosis was classified according to the Academic Research Consortium [8]. To investigate the effect of the intended bioresorption of the device, we examined outcomes during the first and second years separately. Definitions of clinical outcomes per study are described in S1 Table.

**Statistical analysis**

Odds ratios (ORs) with 95% confidence intervals (CIs) were used as summary statistics across all studies and were calculated using a random effects model (Dersimonian and Laird). We also provide results of the fixed-effect model. Treatment effect was not assessed in studies in which no events were reported. Heterogeneity was assessed using Cochran Q and Higgins I². I² values of <25%, 25–50% or >50% indicate low, moderate or high heterogeneity. Cochran Q P <0.10 and I² >50% were considered to be indicative of significant heterogeneity. All analyses were conducted with Revman software (version 5.3).

Primary and secondary outcomes are reported for all included studies in which the outcome of interest was provided. A sensitivity analysis was performed, as detailed in the online supplement. In this analysis, the treatment effect was investigated in studies that included low-risk patients (ABSORB II, ABSORB III, ABSORB Japan, ABSORB China) versus studies that included more complex population (TROFI II, AIDA, EVERBIO and the observational studies, including higher percentage of STEMI, bifurcation, calcification, long lesions etc.). Finally,
separate subgroup analyses for RCTs (low risk of bias) and propensity-matched studies (low/low-moderate risk of bias) were performed.

The risks of adverse events between 0–1 year, 1–2 and 2–3 years were estimated using a landmark population that censored any casualty and lost to follow-up preceding each specific time point.

**Trial sequential analysis**

Meta-analyses may result in type 1 errors due to systematic errors (several forms of bias) or random errors (play of chance) due to sparse data and repeated significance testing when a meta-analysis is updated with new trials [9]. This can result in spurious significant results [10]. Trial sequential analysis (TSA) was introduced to minimize random errors. TSA provides the necessary information for meta-analyses and boundaries that determine whether the evidence is reliable and conclusive. We calculated required information size allowing for a type 1 error of 0.05, type 2 error of 0.20, the control event proportions and effect size calculated from the included trials, and heterogeneity estimated by the diversity (D2) in the included trials. We constructed TSA boundaries based on the O'Brien-Fleming alpha-spending function. Trial Sequence Analysis Software (Copenhagen Trial Unit’s TSA Software; Copenhagen, Sweden) was used.

**Results**

The de-duplicated results yielded 1305 records. Fig 1 shows a flow diagram of the selection process. Based on the exclusion criteria, 1278 records were excluded after title/abstract review. Twenty-seven records remained for full-text analysis, of which 17 were eliminated (short follow-up or editorials). Ultimately, we included 7 RCTs (3 full-length manuscripts, 4 meeting presentations) with a total of 5578 patients: 3258 received the Absorb BVS and 2320 received a second-generation DES. We also included 3 observational studies (2 manuscripts and 1 meeting presentation) with 1742 patients: 749 were implanted with a BVS and 993 with a DES. Weighted median FU was 30.5 months. Table 1 summarizes the main characteristics of the included studies.

**Baseline characteristics**

Across all studies in this meta-analysis, the mean age of patients ranged from 56.0 to 67.3 years; the percentage of men between 70.1% and 81.4%; diabetic patients between 12.8% and 36.1%; and the percentage of patients that presented with an acute coronary syndrome between 9.8% and 100%. In all studies except ABSORB II and EVERBIO, the per protocol prescribed duration of dual antiplatelet therapy (DAPT) was at least 12 months. The percentage of BVS patients using DAPT at 2 years ranged from 5.5% to 66%. The rate of post-dilatation ranged from 15.2% to 82.2% (Table 2).

**Clinical outcomes**

In the TSA for the primary endpoint, the cumulative Z-curve did cross the TSA monitoring boundary, indicating that there were a sufficient number of patients to consider this a valid analysis (Fig 2A). All studies but one (BVS Expand) reported on TLF. Overall, TLF occurred in 617 patients during the mid-term follow-up, with a significantly higher risk in BVS-treated patients (OR 1.34 [95% CI: 1.12–1.60], p = 0.001 and I² = 0%) (Fig 3A). A subanalysis of RCTs showed only a significantly similar increased OR (1.31 [95% CI: 1.08–1.58], p = 0.005 and I² = 0%). The pooled OR across the observational studies was numerically higher, but with a larger 95% CI (OR 1.57 [95% CI: 0.92–2.68, p = 0.10, I² = 0%].
See S2 and S8 Figs for the sensitivity analyses and S3–S7 Figs for fixed effects models of the primary and secondary endpoints.

Secondary endpoints. All-cause mortality occurred in 207 patients, without a statistically significant difference between both patient groups (OR 0.78 [95% CI: 0.56–1.37], p = 0.09, I² = 0%). Results for the pooled RCT and pooled observational study subgroups were similar (Fig 3B).

The risks of myocardial infarction and TLR were significantly increased for BVS compared with DES (Fig 3C and 3D). Finally, patients with BVS had a higher risk for definite or probable device thrombosis, with ORs of 2.82 (95% CI: 1.86–3.89), p<0.001 and I² = 40.3%), 3.48 (95% CI: 2.06–5.87, p<0.001 and I² = 0%) and 2.82 (95% CI: 1.86–4.26, p<0.001 and I² = 0%), respectively, for the total cohort, RCTs only and observational data only (Fig 3E).

Landmark analysis

Table 3 summarizes event rates and ORs in the periods up to 1 year, 1–2 years and 2–3 years (for those studies that reported 1- and 2-year and 3-year results of the outcomes of interest: ABSORB II, ABSORB Japan, ABSORB China, ABSORB III). In the first year, the risks of myocardial infarction and device thrombosis were significantly increased in BVS patients. During the second year, all event rates for both BVS and DES were lower, but the increased risk for BVS remained. The OR for late device thrombosis was quadrupled in BVS-treated patients. In the third year, event rates remained lower and no significant differences between the 2 groups existed anymore. However, the OR for device thrombosis in BVS patients continued to be high.

Definite/Probable device thrombosis

For the secondary endpoint definite or probable device thrombosis, we specifically investigated early (0–30 days), late (31 days-1 year) and very late (> 1 year) device thrombosis (for studies

Table 1. Major characteristics of included studies.

| Study            | Year | Centres, n | BVS/ DES treated Patients, n | Study type | Clinical presentation | Primary Endpoint | Follow-up, yrs. |
|------------------|------|------------|-----------------------------|------------|-----------------------|------------------|-----------------|
| ABSORB II [32]   | 2016 | 46         | 335/ 166                    | RCT        | SAP, established ACS  | Vasomotion & LLL (at 3 yrs.) | 1, 2, 3, 4      |
| ABSORB III [31]  | 2017 | 193        | 1322/ 686                   | RCT        | SAP, established ACS  | TLF (at 1 yr.)    | 1, 2, 3         |
| ABSORB Japan [41]| 2016 | 38         | 266/ 134                    | RCT        | SAP, established ACS  | TLF (at 1 yr.)    | 1, 2, 3         |
| ABSORB China [42]| 2016 | 24         | 238/ 237                    | RCT        | SAP, established ACS  | LLL (at 1 yr.)    | 1, 2, 3         |
| TROFI II [30]    | 2016 | 8          | 95/ 96                      | RCT        | STEMI                 | HS (at 6 months)  | 1, 2, 3         |
| EVERBIO [43]     | 2017 | 1          | 78/ 80                      | RCT        | SAP, ACS, silent ischemia | LLL (at 9 months) | 9 months, 2 yrs. |
| AIDA [44]        | 2017 | 5          | 924/ 921                    | RCT        | SAP, ACS              | TVF (at 2 yrs.)   | Median of 707 days |
| Imori et al. [45]| 2016 | 8          | 214/ 215                    | Propensity matched | ACS                              | MACE             | 2               |
| BVS-Examination [46]| 2016 | 6          | 290/ 290                    | Propensity matched | STEMI                             | POCE (at 1 yr.)  | 1, 2            |
| BVS Expand [47]  | 2017 | 1          | 244/ 488                    | Propensity matched | SAP, UA, NSTEMI, silent ischemia | MACE             | 2               |

ACS: acute coronary syndrome; DOCE: device oriented composite endpoint; HS: healing score; LLL: late lumen loss; MACE: major adverse cardiac events; RCT: randomized controlled trial; SAP: stable angina pectoris; STEMI: ST-elevation myocardial infarction; TLF: target lesion failure; LLL: late lumen loss; TVF: target vessel failure; UAP: unstable angina pectoris

https://doi.org/10.1371/journal.pone.0197119.t001
that reported the outcome of interest at these three time points). Event rates for early thrombosis were 1.07% for BVS versus 0.51% for DES. This resulted in an increased risk for BVS (OR 1.96 [95% CI: 1.01–3.81], p = 0.05). Late device thrombosis event rates were 0.53% for BVS.
Fig 2. 2A and 2B. Trial Sequential Analysis for primary endpoint Target Lesion Failure (A) and secondary endpoint definite/probable device thrombosis (B). The red dotted line represents the trial sequential monitoring boundaries and the futility boundaries. The solid dark red line illustrates the conventional level of significance ($p = 0.05$). The cumulative
versus 0.09% for DES (OR 3.14 [95% CI: 0.83–11.82, p = 0.09]). Rates of very late device thrombosis up to three years were 1.09% for BVS compared to 0.0% for DES (OR 6.10 [95% CI: 1.40–26.65], p = 0.02).

The sensitivity analysis results can be found in S2 Fig.

### A Target lesion failure

| Study or Subgroup | Events | Total | Weight | Odds Ratio M-H, Random, 95% CI, Year |
|-------------------|--------|-------|--------|------------------------------------|
| **Randomized controlled trials** |        |       |        |                                    |
| ABSORB China      | 24     | 160   | 0.53   | 1.29 [0.70, 2.36]                  |
| ABSORB II         | 50     | 144   | 0.36   | 1.10 [0.71, 1.66]                  |
| STEAM II          | 80     | 143   | 0.59   | 1.37 [0.96, 1.95]                  |
| **Subtotal (95% CI)** | 328    | 587   | 0.89   | 1.31 [1.01, 1.70]                  |
| **Total events**  | 37     | 218   |        |                                    |
| **(95% CI)**      | 392    | 290   | 1.89   | 1.34 [1.02, 1.79]                  |
| **Heterogeneity** | Tau^2 = 0.00, I^2 = 37.3%, p = 0.01 | Favour BVS Favours DES |

### B All-cause mortality

| Study or Subgroup | Events | Total | Weight | Odds Ratio M-H, Random, 95% CI, Year |
|-------------------|--------|-------|--------|------------------------------------|
| **Randomized controlled trials** |        |       |        |                                    |
| ABSORB China      | 24     | 160   | 0.53   | 0.33 [0.07, 1.63]                  |
| ABSORB II         | 50     | 144   | 0.36   | 0.72 [0.26, 2.17]                  |
| STEAM II          | 80     | 143   | 0.59   | 0.97 [0.53, 1.81]                  |
| ABSORB Japan      | 39     | 152   | 0.60   | 0.97 [0.58, 1.62]                  |
| **Subtotal (95% CI)** | 282    | 587   | 0.89   | 0.79 [0.51, 1.20]                  |
| **Total events**  | 22     | 170   |        |                                    |
| **(95% CI)**      | 255    | 220   | 1.20   | 0.81 [0.50, 1.33]                  |
| **Heterogeneity** | Tau^2 = 0.12, I^2 = 67.8%, p = 0.05 | Favour BVS Favours DES |

### C All myocardial infarction

| Study or Subgroup | Events | Total | Weight | Odds Ratio M-H, Random, 95% CI, Year |
|-------------------|--------|-------|--------|------------------------------------|
| **Randomized controlled trials** |        |       |        |                                    |
| STEAM II          | 80     | 143   | 0.59   | 2.11 [0.27, 11.8]                  |
| STEAM II          | 80     | 143   | 0.59   | 2.11 [0.27, 11.8]                  |
| **Subtotal (95% CI)** | 328    | 587   | 0.89   | 1.16 [0.50, 2.66]                  |
| **Total events**  | 22     | 170   |        |                                    |
| **(95% CI)**      | 255    | 220   | 1.20   | 1.03 [0.52, 2.07]                  |
| **Heterogeneity** | Tau^2 = 0.12, I^2 = 67.8%, p = 0.05 | Favour BVS Favours DES |

### D Definite/probable device thrombosis

| Study or Subgroup | Events | Total | Weight | Odds Ratio M-H, Random, 95% CI, Year |
|-------------------|--------|-------|--------|------------------------------------|
| **Randomized controlled trials** |        |       |        |                                    |
| STEAM II          | 80     | 143   | 0.59   | 3.13 [0.30, 32.32]                 |
| **Subtotal (95% CI)** | 328    | 587   | 0.89   | 3.13 [0.30, 32.32]                 |
| **Total events**  | 22     | 170   |        |                                    |
| **(95% CI)**      | 255    | 220   | 1.20   | 3.13 [0.30, 32.32]                 |
| **Heterogeneity** | Tau^2 = 0.12, I^2 = 67.8%, p = 0.05 | Favour BVS Favours DES |

### E Target lesion revascularization

| Study or Subgroup | Events | Total | Weight | Odds Ratio M-H, Random, 95% CI, Year |
|-------------------|--------|-------|--------|------------------------------------|
| **Randomized controlled trials** |        |       |        |                                    |
| ABSORB II         | 50     | 144   | 0.36   | 1.16 [0.54, 2.53]                  |
| STEAM II          | 80     | 143   | 0.59   | 1.16 [0.54, 2.53]                  |
| **Subtotal (95% CI)** | 328    | 587   | 0.89   | 1.16 [0.54, 2.53]                  |
| **Total events**  | 22     | 170   |        |                                    |
| **(95% CI)**      | 255    | 220   | 1.20   | 1.16 [0.54, 2.53]                  |
| **Heterogeneity** | Tau^2 = 0.12, I^2 = 67.8%, p = 0.05 | Favour BVS Favours DES |

Fig 3. 3A – 3E. Forest plots (random effects models) for primary and secondary endpoint of biodegradable vascular scaffolds versus drug-eluting stents. (A) Target lesion failure, (B) All-cause mortality, (C) All myocardial infarction, (D) Target lesion revascularization. RCTs reported ischemia-driven TLR and observational studies reported all TLR. (E) Definite/probable device thrombosis. CI: confidence interval; M-H: Mantel-Haenszel; OR: odds ratio.

https://doi.org/10.1371/journal.pone.0197119.g003

https://doi.org/10.1371/journal.pone.0197119.g002

https://doi.org/10.1371/journal.pone.0197119.g001
Quality assessment

Quality assessments for both RCTs and observational studies are provided in the S2 and S3 Tables. All RCTs had a low risk of bias, while the observational studies had a low/low-moderate risk of bias (all scored 7 out of 9). To assess a possible publication bias, a funnel plot for TLF was derived (S1 Fig).

Discussion

This study included 7320 patients, to report on the mid-term clinical outcomes of the Absorb BVS compared with second-generation DES. Compared to other meta-analyses [11–14], our analysis included the RCTs and complemented only with propensity matched registries to include the highest quality data available for more complex patients. Using this strategy we were able to perform a sub analysis for RCT and propensity match series representing the more complex none RCT patients and a separate analysis for 2 to 3 year outcomes. Furthermore, a trial sequential analysis was performed and also, several sensitivity analyses were done such an analysis of more complex patients versus non-complex patients.

The main findings of this meta-analysis are: 1) BVS-treated patients were at higher risk for TLF, MI, TLR and device thrombosis compared with second-generation DES, across all studies included in this meta-analysis; 2) this did not result in an increased risk of all-cause mortality; 3) based on studies that have reported clinical outcomes of interest at 1, 2 and 3 years of follow-up, risks of TLF, MI, TLR and especially the risk of very late device thrombosis, continued to be higher for BVS in following years after device implantation.

In our study, propensity matched registries were included. There are some advantages of registries over clinical trials. Firstly, registries handle less strict in- and exclusion criteria and therefore create a more ‘real-world’ patient population [15]. Results originating from registries are better generalizable. Secondly, registries often make use of longer-term follow-up then duration of follow-up observed in RCTs. Thirdly, the larger amount of events makes the identification of rare events, such as ScT, possible. Fourth, as registries integrate data less selected patients, receiving care in diverse clinical settings, they are able to better investigate specific subgroups that are often underrepresented in clinical trials.

Initial study designs for BVS, based on the concept of temporary vascular support, hypothesized non-inferiority at one year and a reduction in TLF of approximately 50% beyond the first year. In this analysis, we demonstrated that event rates were highest during the first year after PCI and, for all endpoints except all-cause mortality; the use of BVS was associated with significantly higher risks of events. The mid-term results in this meta-analysis are in line with previous results [12, 16–21]. Beyond 1 year, event rates were lower than during the first year,
but outcomes such as device thrombosis, myocardial infarction and the primary endpoint--
TLF--remained not in favour of BVS.

Four RCT’s reported their three-year results and one RCT presented four-year results. All
revealed continued higher event rates for BVS. During the EuroPCR 2017 congress, longer
term data of several large single-arm registries, that included higher percentages of complex
patients, was presented and with varying results [22].

**Definite/Probable device thrombosis**

In our study, we demonstrated that the risk of definite device thrombosis was almost three
times higher for BVS. Meta-analyses investigating device thrombosis in BVS compared with
DES have reported an increased risk of device thrombosis for BVS [5, 23, 24]. Multiple factors
have been reported to be associated with scaffold thrombosis, such as a suboptimal implanta-
tion strategy, overlap, ostial lesions and decreased left ventricular ejection fraction [25]. More-
over, the first-generation BVS has a strut thickness considerably larger than the competitor
metallic DES and similar to first-generation metallic DES. Scaffold thrombosis might be trig-
gered by the smaller minimum lumen diameter and minimum lumen area at the end of the
procedure, as previously demonstrated [26]. This has the most impact on smaller vessels (with
a diameter <2.5 mm visual or 2.25 mm by quantitative coronary analysis (QCA).

Early device thrombosis is generally considered to be procedure-related, when the charac-
teristics of the device and operators experience are important factors.

The resorption process of the BVS might influence the mechanisms for very late scaffold
thrombosis. It has been postulated that the disintegration of uncovered and malapposed struts
(due to resorption-related scaffold discontinuity) might trigger the inflammatory process and
thrombus formation, potentially for up to 3 years (18, 26, 27).

**Recent setback**

Recently, the ABSORB BVS suffered a setback after the 3-year results of the ABSORB II trial
demonstrated similar vasomotion between BVS and everolimus-eluting DES and a greater late
lumen loss for BVS. [27, 28] The FDA came with a safety alert after the 2-year results of the
largest RCT, the ABSORB III, were presented during the ACC congress in March 2017. The
AIDA trial even published their 2-year results earlier than expected after the safety monitoring
board recommended to release the preliminary data due to safety concerns (hazard ratio of
3.87 for device thrombosis at 2 years; 95% CI: 1.78–8.42; p = <0.001). As a consequence, the
current generation BVS has been taken out of the market. Just recently, a Task Force of ESC
and EAPCI stated that bioresorbable scaffolds should not be preferred above the current used
metallic DES [29]. These unfavourable findings were again confirmed during the 2017 TCT
congress in Denver, USA on October the 31th. [30–32]

**Possible solutions and future outlook**

It remains uncertain whether implantation technique could improve outcomes. The basic con-
cept of optimal implantation includes proper lesion preparation, adequate sizing (avoiding
small vessels <2.5 mm) and high-pressure post-dilatation, also known as PSP. In retrospective
analyses, this implantation strategy showed a reduction in TLF [25] [22, 33–35]. Also, the
30-day ABSORB IV results revealed lower device thrombosis rates, when implantation of
stents/ scaffolds in small vessels was minimalized. [36] The prospective study ‘IT-DIAPPEARS’
showed that when a predefined implantation technique was performed, one-year outcomes
were favourable with a def/ prob ScT rate of 0.9%. [37] However, our meta-analysis was not
able to correctly assess the influence of PSP on procedural and clinical outcomes, as the included studies did not apply high rates of dedicated implantation strategy.

Furthermore, whether DAPT prolongation could prevent late occurrence of scaffold thrombosis was to be investigated. DAPT termination is a risk factor for device thrombosis, and a possible relationship between scaffold thrombosis and DAPT termination has been described. However, information on the precise duration of DAPT after BVS implantation is lacking and, up to this moment, no dedicated studies exist on this important issue. A recently published review has suggested several considerations for DAPT duration in BVS patients [38]. In metal stents, prolongation of DAPT up to 30 months showed to reduce thrombotic events [39]. The new generation device should have thinner struts, better mechanical properties and shorter resorption time to facilitate easy implantation strategies and to prevent intraluminal dismantling [40].

Limitations
The most important limitation is the use of unpublished data in the form of meeting presentations. Secondly, the meta-analysis was performed using study-level data rather than patient-level data, so time-to-event curves were not possible. Thirdly, heterogeneity existed in baseline characteristics of included patients and also in protocols, study designs and definitions across the studies. Furthermore, the patients included in the RCTs (which provided most patients) were highly selected (except for AIDA) and, therefore, extrapolation to the real world is difficult. Besides, we were not able to completely exclude potential confounders in the observational registries. However these studies were based on propensity matching. Fourthly, the large AIDA RCT had a median follow-up duration of 1.93 years (range 1−3.3 years); thus this trial did not report outcomes at exactly 2 years.

Longer follow-up will be necessary to get a better view of the low-frequency endpoint mortality.

To assess possible publication bias, we provided a funnel plot in S1 Fig. However, this plot should be interpreted with caution as we included ten studies. There was also a lack of important information on DAPT status (duration of DAPT, reasons for interruption or early termination, type of P2Y₁₂ inhibitor). Lastly, the current data only apply for the Absorb BVS and not for other bioresorbable devices.

Conclusions
At mid-term follow-up, patients treated with Absorb BVS showed a higher risk of TLF, myocardial infarction, TLR and definite or probable device thrombosis. Beyond 1 year, it was mainly the risk of late device thrombosis that was increased. However, this did not result in a higher risk of all-cause mortality. Despite these unfavourable mid-term outcomes, long-term follow-up will be necessary to investigate any potential late benefits of BVS over DES as this device was not able to show any clinical benefit up to 3 years. Specific registries and post-hoc analyses of larger RCTs identified potential improvements in patient and lesion selection. A device specific implantation strategy is another factor that can result in better outcomes. As long as this has not been demonstrated in prospective and dedicated studies such as ABSORB III (NCT01751906), ABSORB IV (NCT02173379) and Compare Absorb (NCT02486068) operators should not use this version in routine practice.

Supporting information
S1 Fig. Funnel plot for the primary endpoint.
(DOCX)
S2 Fig. Sensitivity analysis for TLF and device thrombosis. Non-Complex Studies Versus Complex Studies. Random effects effects model. CI: confidence interval; M-H: Mantel-Haenszel; OR: odds ratio.

S3 Fig. Target lesion failure. Fixed effects model. CI: confidence interval; M-H: Mantel-Haenszel; OR: odds ratio.

S4 Fig. All-cause mortality. Fixed effects model. CI: confidence interval; M-H: Mantel-Haenszel; OR: odds ratio.

S5 Fig. Myocardial infarction. Fixed effects model. CI: confidence interval; M-H: Mantel-Haenszel; OR: odds ratio.

S6 Fig. Target lesion revascularization. Fixed effects model. CI: confidence interval; M-H: Mantel-Haenszel; OR: odds ratio.

S7 Fig. Definite/Probable device thrombosis. Fixed effects model. CI: confidence interval; M-H: Mantel-Haenszel; OR: odds ratio.

S8 Fig. Sensitivity analysis for TLF. RCTs versus propensity matched studies. Random effects effects model. CI: confidence interval; M-H: Mantel-Haenszel; OR: odds ratio.

S1 Text. Literature search in the most important online databases.

S1 Table. Definitions of clinical outcomes per study. CABG: coronary artery bypass grafting; CK: creatine kinase; CK-MB: creatine kinase myoglobulin; ID-TLR: ischemia-driven target lesion revascularization; MI: myocardial infarction, ULN: upper limit of normal.

S2 Table. Assessment of risk of bias for randomized controlled trials. CEC: clinical event committee; IWRS: interactive web-based response system.

S3 Table. Quality assessment for observational studies. Score of nine is maximum score (= lowest risk of bias).

S4 Table. Checklist for PRISMA guidelines.

Acknowledgments
We would like to thank Wichor Bramer and Taulant Muka for their valuable help.

Author Contributions
Conceptualization: Cordula M. Felix, Yoshinobu Onuma, Robert Jan M. van Geuns.
Data curation: Cordula M. Felix, Victor J. van den Berg.
Formal analysis: Cordula M. Felix.
Methodology: Cordula M. Felix, Victor J. van den Berg, Sanne E. Hoeks, Eric Boersma, Robert Jan M. van Geuns.
Project administration: Robert Jan M. van Geuns.
Supervision: Yoshinobu Onuma, Robert Jan M. van Geuns.
Validation: Cordula M. Felix.
Visualization: Cordula M. Felix.
Writing – original draft: Cordula M. Felix, Victor J. van den Berg, Yoshinobu Onuma.
Writing – review & editing: Cordula M. Felix, Victor J. van den Berg, Sanne E. Hoeks, Jiang Ming Fam, Mattie Lenzen, Eric Boersma, Peter C. Smits, Patrick W. Serruys, Yoshinobu Onuma, Robert Jan M. van Geuns.

References

1. Steinvil A, Rogers T, Torguson R, Waksman R. Overview of the 2016 U.S. Food and Drug Administration Circulatory System Devices Advisory Panel Meeting on the Absorb Biodegradable Vascular Scaffold System. JACC Cardiovasc Interv. 2016; 9(17):1757–64. https://doi.org/10.1016/j.jcin.2016.06.027 PMID: 27609249.

2. Stone GW, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, et al. 1-year outcomes with the Absorb biodegradable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016. https://doi.org/10.1016/S0140-6736(15)01399-9 PMID: 26825231.

3. Banach M, Serban MC, Sahebkar A, Garcia-Garcia HM, Mikhailidis DP, Martin SS, et al. Comparison of clinical outcomes between biodegradable vascular stents versus conventional drug-eluting and metallic stents: a systematic review and meta-analysis. EuroIntervention. 2016; 12(2):e175–89. https://doi.org/10.4244/EIJY16M06_02 PMID: 27290677.

4. Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, et al. Everolimus-eluting biodegradable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2016; 387(10018):537–44. https://doi.org/10.1016/S0140-6736(15)00979-4 PMID: 26597771.

5. Toyota T, Morimoto T, Shiomi H, Yoshikawa Y, Yaku H, Yamashita Y, et al. Very Late Scaffold Thrombosis of Biodegradable Vascular Scaffold: Systematic Review and a Meta-Analysis. JACC Cardiovasc Interv. 2017; 10(1):27–37. https://doi.org/10.1016/j.jcin.2016.10.027 PMID: 28057284.

6. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5):336–41. https://doi.org/10.1016/j.ijsu.2010.02.007 PMID: 20171303.

7. Higgings JPY GS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]2011.

8. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17):2344–51. https://doi.org/10.1161/CIRCULATIONAHA.106.685313 PMID: 17470709.

9. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol. 2009; 38 (1):276–86. https://doi.org/10.1093/ije/dyn179 PMID: 18824467.

10. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008; 61(1):64–75. https://doi.org/10.1016/j.jclinepi.2007.03.013 PMID: 18083463.

11. Zhang XL, Zhi QQ, Kang LN, Li XL, Xu B. Mid- and Long-Term Outcome Comparisons of Everolimus-Eluting Biodegradable Scaffolds Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-Analysis. Ann Intern Med. 2017. https://doi.org/10.7326/M17-1101 PMID: 29049539.

12. Mahmoud AN, Barakat AF, Eligyay AY, Schneibel E, Mertias A, Abuzaid A, et al. Long-Term Efficacy and Safety of Everolimus-Eluting Biodegradable Vascular Scaffolds Versus Everolimus-Eluting Metallic...
Mid-term outcomes of BVS Vs DES: A systematic review and meta-analysis

Stents: A Meta-Analysis of Randomized Trials. Circ Cardiovasc Interv. 2017; 10(5). https://doi.org/10.1161/CIRCINTERVENTIONS.117.005286 PMID: 28468954.

13. Polimeni A, Anadoli R, Munzel T, Indolfi C, De Rosa S, Gori T. Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs. BMC Cardiovasc Disord. 2017; 17(1):147. https://doi.org/10.1186/s12872-017-0586-2 PMID: 28592227.

14. Kang SH, Gogas BD, Jeon KH, Park JS, Lee W, Yoon CH, et al. Long-term Safety of Bioresorbable Scaffolds Insights from a Network Meta-Analysis Including 91 Trials. EuroIntervention. 2017. https://doi.org/10.2444/EU-J-D-17-00646 PMID: 29278353.

15. de Boer SP, van Leeuwen MA, Cheng JM, Oemrawsingh RM, van Geuns RJ, Serruys PW, et al. Trial participation as a determinant of clinical outcome: differences between trial-participants and Every Day Clinical Care patients in the field of interventional cardiology. Int J Cardiol. 2013; 169(4):305–10. https://doi.org/10.1016/j.ijcard.2013.09.011 PMID: 24144926.

16. Nairooz R, Saad M, Sardar P, Aronow WS. Two-year outcomes of bioresorbable vascular scaffolds versus drug-eluting stents in coronary artery disease: a meta-analysis. Heart. 2017. https://doi.org/10.1136/heartjnl-2016-310886 PMID: 28115471.

17. Sorrentino S, Giustino G, Mehran R, Kini AS, Sharma SK, Faggioni M, et al. Everolimus-Eluting Biodegradable Scaffolds versus Metallic Everolimus-Eluting Stents: Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol. 2017.

18. Cassese S, Robert BA, Juni P, Wykrzykowska JJ, Puricel S, Ndrepepa G, et al. Mid-term clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomized trials. EuroIntervention. 2017. https://doi.org/10.2444/EU-J-D-17-00492 PMID: 28671552.

19. Ali ZA, Serruys PW, Kimura T, Gao R, Ellis SG, Kereiakes DJ, et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data study. Lancet. 2017. https://doi.org/10.1016/S0140-6736(17)31470-8 PMID: 28732815.

20. Montone RA, Niccoli G, De Marco F, Minelli S, D’Ascenzo F, Testa L, et al. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials. Circulation. 2017; 135(22):2145–54. https://doi.org/10.1161/CIRCULATIONAHA.117.028479 PMID: 28559495.

21. Ha FJ, Nerlekar N, Cameron JD, Bennett MR, Meredith IT, West NE, et al. Midterm Safety and Efficacy of ABSORB Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent: An Updated Meta-Analysis. JACC Cardiovasc Interv. 2017; 10(3):308–10. https://doi.org/10.1016/j.jcin.2016.11.054 PMID: 28183474.

22. Serruys PW, Katsiki A, Onuma Y. Long-term data of BRS presented at EuroPCR 2017 (Friday, 19 May). EuroIntervention. 2017; 13(5):e515–e21. https://doi.org/10.4244/EIJV13I5A82 PMID: 28781248.

23. Lipinski MJ, Escarcega RO, Baker NC, Bennett HA, Gaglia MA Jr., Torguson R, et al. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis. JACC Cardiovasc Interv. 2016; 9(1):12–24. https://doi.org/10.1016/j.jcin.2015.09.024 PMID: 26762906.

24. Kang SH, Chae IH, Park JJ, Lee HS, Kang DY, Hwang SS, et al. Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials. JACC Cardiovasc Interv. 2016; 9(12):1203–12. https://doi.org/10.1016/j.jcin.2016.03.038 PMID: 27726260.

25. Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, et al. Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. J Am Coll Cardiol. 2016; 67(8):921–31. https://doi.org/10.1016/j.jacc.2015.12.019 PMID: 26916481.

26. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015. https://doi.org/10.1056/NEJMoa1509038 PMID: 26457558.

27. Ellis S, Kereiakes D, Stone GW. Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results. American College of Cardiology Congress 2017 2017:Oral presentation.

28. Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrie D, Piek JJ, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016. https://doi.org/10.1016/S0140-6736(16)32050-5 PMID: 27806897.

29. Byrne RA, Stefanini GF, Capodanno D, Onuma Y, Baumbach A, Escaned J, et al. Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary
mid-term outcomes of BVS Vs DES: A systematic review and meta-analysis

30. Sabate M, Asano T. Comparison of the ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug-Eluting Metal Stent (Xience) in Acute ST-Elevation Myocardial Infarction: 3-year results of TROFI II Study and correlations with the 6-month OCT findings. Oral presentation at TCT congress. 2017;October 31st 2017.

31. Ellis SG, Kereiakes DJ, Stone GW. Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial. Oral presentation at TCT congress. 2017;October 31st 2017.

32. Chevalier B, Serruys PW. The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the XIENCE Everolimus Eluting Stent. Oral presentation at TCT congress. 2017;October 31st 2017.

33. Ortega-Paz L, Capodanno D, Gori T, Nef H, Latib A, Caramanno G, et al. Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. EuroIntervention. 2017. https://doi.org/10.4244/EIJ-D-16-00974 PMID: 28246060.

34. Tanaka A, Latib A, Kawamoto H, Jabbour RJ, Sato K, Miyazaki T, et al. Clinical outcomes of a real world cohort following bioresorbable vascular scaffold implantation utilizing an optimized implantation strategy. EuroIntervention. 2016. https://doi.org/10.4244/EIJ-D-16-00247 PMID: 27746400.

35. Markovic S, Kugler C, Rottbauer W, Wohrle J. Long-term clinical results of bioresorbable absorb scaffolds using the PSP-technique in patients with and without diabetes. J Interv Cardiol. 2017; 30(4):325–30. https://doi.org/10.1111/jioc.12392 PMID: 28568564.

36. Stone GW. Outcomes of Absorb Bioresorbable Scaffolds with Improved Technique in an Expanded Patient Population: The ABSORB IV Randomized Trial. Oral presentation at TCT congress. 2017;October 31st 2017.

37. Testa L, De Carlo M, Petrolini A, Rapetto C, Varbella F, Cortese B, et al. One-year clinical results of the Italian diffuse/multivessel disease ABSORB prospective registry (IT-DISAPPEAR). EuroIntervention. 2017; 13(4):424–31. https://doi.org/10.4244/EIJ-D-17-00246 PMID: 28504219.

38. Capodanno D, Angiolillo DJ. Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Published Data, Practical Recommendations, and Future Directions. JACC Cardiovasc Interv. 2017; 10(5):425–37. https://doi.org/10.1016/j.jcin.2016.12.279 PMID: 28279311.

39. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371(23):2155–66. https://doi.org/10.1056/NEJMoa1409312 PMID: 25399658.

40. Seth A, Onuma Y, Costa R, Chandra P, Bahl VK, Manjunath CN, et al. First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial. EuroIntervention. 2017; 13(4):415–23. https://doi.org/10.4244/EIJ-D-17-00306 PMID: 28504218.

41. Kozuma K, Tanabe K, Kimura T. 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting Stent in de novo Native Coronary Artery Lesions. EuroPCR congress 2017. Oral presentation on May 16.

42. Gao R. Randomized comparison of everolimus-eluting bioresorbable vascular scaffold vs. everolimus-eluting metallic stents in patients with coronary artery disease: 3-year clinical outcomes from ABSORB China. EuroPCR congress 2017. Oral presentation on May 16.

43. Arroyo D, Gendre G, Schukraft S, Kallinkou Z, Muller O, Baeriswyl G, et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial. Int J Cardiol. 2017. https://doi.org/10.1016/j.ijcard.2017.05.053 PMID: 28576627.

44. WykrzykowskaJJ,KraakRP,HofmaSH,vanderSchaalRJ,ArkenboutEK,AJJU,etal.BioresorbableScaffoldsversusMetallicStentsinRoutinePCI.NEnglJMed.2017;376(24):2319–28.https://doi.org/10.1056/NEJMoa1614954 PMID: 28402237.

45. Imori Y, D’Ascenzo F, Gori T, Munzel T, Fabrizio U, Campo G, et al. Impact of postdilation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter "real-world" registry. Circ Cardiovasc Qual Outcomes. 2016. https://doi.org/10.1001/circoutcomes.2016.0052 PMID: 27515481.

46. Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, et al. ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison. Int J Cardiol. 2016; 214:483–4. https://doi.org/10.1016/j.ijcard.2016.04.016 PMID: 27096965.
47. Felix CM FJ, Diletti R, Regar ES, van Mieghem NM, Onuma Y, van Geuns RJ. Two-years Clinical Outcomes Of The ABSORB BVS Compared EES: A Propensity Matched Analysis Of The BVS Expand Registry. Presented during LBCT of CRT. 2017.